New drug cocktail targets tough thyroid cancers

NCT ID NCT07235566

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II trial tests a combination of two drugs—MRG003 and pucotenlimab—in 60 people with a rare and aggressive form of thyroid cancer that cannot be removed by surgery. The goal is to see if the treatment can shrink tumors and control the disease. Participants receive the drugs every three weeks until their cancer progresses or side effects become too severe.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MRG003 (a targeted drug) combined with pucotenlimab (an immunotherapy)
What this could lead to: If it works, this could offer a new treatment option for people with advanced thyroid cancer that has stopped responding to other therapies.
What could go wrong: This is an early phase II trial with only 60 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ANAPLASTIC THYROID CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

poorly differentiated thyroid gland carcinoma thyroid cancer thyroid gland undifferentiated (anaplastic) carcinoma Thyroid Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

THYROID CANCER

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.